COVID-19 IN CHRONIC MYELOID LEUKEMIA PATIENTS ¿ BRAZILIAN EXPERIENCE KBB Pagnano; AC Toreli; AT Quixadá; L Perobelli; VAM Funke; FS Seguro; I Bendit; LVDN Fechio; J Sapelli; J Bortolini; MS Moura; AG Lourenço; NN Gonçalves; M Conchon; F Nucci; LC Palma; POM Hokama; LL Almeida; CA Souza; C Boquimpani;

IMMUNE MATURATION AND CHECKPOINT DYNAMICS DURING TYROSINE KINASE INHIBITOR DOSE REDUCTION PREDICT RELAPSE RISK IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDERGOING TREATMENT DISCONTINUATION LS Binelli; LC Palma; CAB Garcia; M Medeiros; AG de Carvalho; BL Adjafre; LO Marani; PS Scheucher; JLS Schiavinato; PMM Garibaldi; RL Pacca; FS Seguro; RS Tavares; LL Almeida; RS Welner; KBB Pagnano; LL de Figueiredo-Pontes;

TREATMENT-FREE RESPONSE USING BRAZILIAN IMATINIB COPIES AS FIRST LINE -RESULTS FROM TWO PROSPECTIVE CLINICAL TRIALS RT Centrone; FS Seguro; M Bellesso; L Nardinelli; I Bendit; A Alves; V Rocha;